HR Execs on the Move

Transcarent

www.transcarent.com

 
Transcarent is a new consumer-directed health and care platform for employees of self-insured employers and their families. Using a combination of software, technology, Health Guides and data science, Transcarent empowers consumers with unbiased information, trusted guidance and access to high-value care.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Jerrod Helms
Chief Sales Officer Profile
Timothy Rosa
Chief Marketing Officer Profile
Jennifer Rocha
Director, People Operations Profile
Melinda Lesser
People Operations Director Profile
Meghann Cook
Director Talent Acquisition Profile

Similar Companies

Business Dynamics Limited

Business Dynamics Limited is a Mineola, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Levo Usa Inc

Levo Usa Inc is a Peachtree City, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pathway to Living

Since 1997, Pathway to Living has been helping older adults fulfill dreams and accomplish goals – every day. People are choosing Pathway as home because they need someone to guide them down their path, not stand in the way. We are the new generation of senior living – a tailored wellness program accompanied with a vibrant and inspirational way of living is what sets Pathway to Living apart from the rest. Join the movement, discover your Pathway.

Gather Health

Gather Health is a company that provides primary care to transform the lives of older adults on Medicare. Their approach is to provide care thats kind, comforting, and helps patients feel better. They have a full team of healthcare professionals who u...

Telesta Therapeutics

Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.